Sokal Index for Chronic Myelogenous Leukemia (CML)
Predicts survival of CML based on clinical and lab information.
Use to predict prognosis at the time of CML diagnosis, before starting treatment.
Advice
Whether the patient meets milestones for cytogenetic and molecular response is more predictive of outcome once therapy is started.
Management
Although the Sokal Score has limited usefulness outside of clinical trials today, in general, low and intermediate risk patients can be started on standard dose imatinib, and high risk patients should be considered for newer generation TKIs or be monitored more closely to ensure complete molecular response.
Critical Actions
Can only be applied in a newly-diagnosed patient prior to starting therapy.